| Literature DB >> 24443808 |
Rebecca A Rolfe, Niamh C Nowlan, Elaine M Kenny, Paul Cormican, Derek W Morris, Patrick J Prendergast, Daniel Kelly, Paula Murphy1.
Abstract
BACKGROUND: Mechanical stimulation is necessary for regulating correct formation of the skeleton. Here we test the hypothesis that mechanical stimulation of the embryonic skeletal system impacts expression levels of genes implicated in developmentally important signalling pathways in a genome wide approach. We use a mutant mouse model with altered mechanical stimulation due to the absence of limb skeletal muscle (Splotch-delayed) where muscle-less embryos show specific defects in skeletal elements including delayed ossification, changes in the size and shape of cartilage rudiments and joint fusion. We used Microarray and RNA sequencing analysis tools to identify differentially expressed genes between muscle-less and control embryonic (TS23) humerus tissue.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24443808 PMCID: PMC3905281 DOI: 10.1186/1471-2164-15-48
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Overview of gene expression profiling approach used. A) Images of control and Pax3 mutant humeri at Theiler stage 23 dissected prior to RNA extraction (right hand image); the images on the left are external views of stage and genotype matched 3D scanned specimens stained to reveal the morphology and ossification more clearly. White arrow heads indicate the elbow joint and shoulder joint line and red arrow heads the ossification site, a visible reduction is apparent in the mutant compared to the control in each case. B) Work-flow of Microarray and RNA-sequencing data analysis.
Figure 2Transcriptome Profiling of the developing humerus at TS23 by RNA-seq, (A) The number of genes (y-axis) with increasing relative expression levels represented by transcript read counts as indicated. (B) The relative expression of selected genes represented by read counts (Log10) (y-axis). Collagen genes and signalling pathways genes are grouped: TGFβ (including TGFβ, BMP and GDF ligands, receptors and agonists), FGF (ligands and receptors), HH (ligands, receptors and intracellular modulators), Wnt (Wnt ligands and agonists (Wnt, Rspo), receptors (Fzd) and co-receptors (Kremen, Lrp), antagonists (Sfrp, Dkk) Intracellular components (Sost, Dvl, Ctnnb) and nuclear components (Tcf, Lef)) and a selection of ‘other’ genes associated with skeletal development. Squares indicate ligands and modulators, triangles indicate receptors.
Differentially expressed genes (p ≤0.05) with fold change values ≥ 2 revealed by Microarray and RNA-Seq analysis and Combined
| Total number of differentially expressed transcripts | 374 | 1,037 | 1,132 | |||
| | ||||||
| Independent named genes | 282 | 87 | 419 | 618 | 680 | 452 |
| Putative uncharacterized proteins/unknown genes | 2 | 3 | - | - | - | - |
| 284 | 90 | 419 | 618 | |||
Figure 3Venn diagrams representing the overlap of independent genes detected as differentially expressed (up-regulated and down-regulated; cut off criteria p ≤ 0.05, and fold change ≥2) from the microarray and RNA seq analysis, as indicated.
Fold change in expression level of selected genes in mutant humeri compared to control humeri revealed by Microarray, RNA seq and qRT-PCR
| Fibroblast growth factor 4 | Down-regulated | 41.05 | #No numerical value | 35.24*** | |
| Cartilage intermediate layer protein, nucleotide pyrophosphohydrolase | Down-regulated | 9.73 | 9.76 | 11.3*** | |
| Retinoid X receptor gamma | Down-regulated | 7.05 | 12.29 | 5.25** | |
| Delta-like 1 | Down-regulated | 2.21 | 3.16 | 1.78* | |
| Secreted phospoprotein 1 | Down-regulated | 5.23(ns) | 2.9 | 2.59* | |
| V-set and transmembrane domain containing 2A | Up-regulated | 8.56 | 3.09 | 14.17** | |
| c-fos induced growth factor | Up-regulated | 3.52 | 3.17 | 4.06** | |
| Fibroblast growth factor 10 | Up-regulated | 2.48 | 2.14 | 3.28 | |
| Secreted frizzled-related protein 2 | Up-regulated | 2.62 | 2.09 | 3.38* |
#No numerical value for fold change as no transcripts detected in the mutant.
***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05 indicates significance of differential expression from qRT-PCR.
p ≤ 0.05 for all microarray and RNA-seq differences except Spp1 in the Microarray (ns).
Enrichment of gene groups down-regulated in muscle-less humeri based on GO terms under subontologies biological process and cellular component
| 155 | 2.73 × 10-15 to 0.0084 | ||
| | GO:0048856: Anatomical structure development | 134 | 2.73 × 10-15 |
| GO:0032502: Developmental process | 155 | 1.52 × 10-14 | |
| GO:0048513: Organ development | 107 | 4.23 × 10-13 | |
| GO:0007275: Multicellular organismal development | 142 | 4.92 × 10-13 | |
| GO:0048731: System development | 122 | 5.57 × 10-13 | |
| GO:0009888: Tissue development | 58 | 8.37 × 10-13 | |
| GO:0030154: Cell differentiation | 94 | 8.86 × 10-10 | |
| GO:0048869: Cellular developmental process | 96 | 1.67 × 10-9 | |
| GO:0048468: Cell development | 45 | 2.66 × 10-7 | |
| GO:0009887: Organ morphogenesis | 38 | 6.12 × 10-5 | |
| GO:0001756: Somitogenesis | 8 | 2.61 × 10-4 | |
| GO:0035282: Segmentation | 9 | 2.66 × 10-4 | |
| GO:0009952: Anterior/posterior pattern formation | 13 | 0.0033 | |
| GO:0009790: Embryonic development | 34 | 0.0074 | |
| GO:0043009: Chordate embryonic development | 24 | 0.0075 | |
| GO:0009792: Embryonic development ending in birth | 24 | 0.0084 | |
| 30 | 5.30 × 10-19 to 0.0995 | ||
| Biological process | GO:0030029: Actin filament-based process | 25 | 1.45 × 10-9 |
| GO:0030036: Actin cytoskeleton organization | 23 | 1.08 × 10-8 | |
| GO:0007010: Cytoskeleton organization | 31 | 1.50 × 10-7 | |
| GO:0007015: Actin filament organization | 5 | 0.0995 | |
| GO:0015629: Actin cytoskeleton | 39 | 5.30 × 10-19 | |
| Cellular component | GO:0005856: Cytoskeleton | 86 | 2.20 × 10-14 |
| GO:0016459: Myosin complex | 21 | 1.26 × 10-15 | |
| GO:0032982: Myosin filament | 11 | 2.32 × 10-12 | |
| GO:0044430: Cytoskeletal part | 51 | 1.16 × 10-6 | |
| GO:0005884: Actin filament | 5 | 0.0134 | |
| 31 | 4.78 × 10-5 to 0.0899 | ||
| GO:0007154: Cell communication | 32 | 4.78 × 10-5 | |
| GO:0007267: Cell-cell signalling | 23 | 1.33 × 10-4 | |
| GO:0007169: Transmembrane protein tyrosine kinase signalling | 17 | 3.85 × 10-4 | |
| GO:0007167: Enzyme linked receptor protein signalling pathway | 20 | 0.0011 | |
| GO:0008543: Fibroblast growth factor receptor signalling pathway | 5 | 0.0139 | |
| GO:0045168: Cell-cell signalling involved in cell fate specification | 4 | 0.0271 | |
| GO:0040036: Regulation of fibroblast growth factor signalling | 3 | 0.0451 | |
| GO:0043409: Negative regulation of MAPKKK cascade | 3 | 0.0614 | |
| GO:0007219: Notch signalling pathway | 5 | 0.0899 | |
All GO terms are associated with the subontology “Biological Process” except where indicated under Cytoskeleton, where Cellular Component was also used.
1P-value of enrichment of GO terms using DAVID analysis software; similar results were found with GOstat.
Enrichment of gene groups up-regulated in muscle-less humeri based on GO terms under subontologies biological process and cellular component
| 32 | 1.99 × 10-10 to 0.0842 | ||
| GO:0007155: Cell adhesion | 41 | 1.99E-10 | |
| GO:0022610: Biological adhesion | 41 | 2.12E-10 | |
| GO:0007156: Homophilic cell adhesion | 15 | 4.95 × 10-7 | |
| GO:0016337: Cell-cell adhesion | 19 | 9.38 × 10-6 | |
| GO:0043062: Extracellular structure organization | 9 | 0.0223 | |
| GO:0030198: Extracellular matrix organisation | 6 | 0.0842 | |
| 33 | 3.45 × 10-9 to 0.0148 | ||
| GO:0007267: Cell-cell signalling | 27 | 3.45 × 10-9 | |
| GO:0007154: Cell communication | 33 | 2.05 × 10-9 | |
| GO:0007223: Wnt receptor signalling pathway, calcium modulating pathway | 7 | 0.0092 | |
| GO:0016055: Wnt receptor signalling pathway | 4 | 0.0104 | |
| GO:0008589: Regulation of smoothened signalling pathway | 9 | 0.0105 | |
| GO:0010648: Negative regulation of smoothened signalling pathway | 4 | 0.0135 | |
| GO:0048010: Vascular endothelial growth factor receptor signalling pathway | 10 | 0.0288 | |
| GO:0007169: Transmembrane receptor protein tyrosine kinase signalling pathway | 3 | 0.0402 | |
| GO:0007167: Enzyme linked receptor protein signalling pathway | 12 | 0.0051 | |
| GO:0007165: Signal transduction | 80 | 0.0148 | |
| [ | 4.38 × 10-6 to 0.0083 | ||
| GO:0048731: System development | 78 | 4.38 × 10-6 | |
| GO:0048856: Anatomical structure development | 81 | 8.42 × 10-6 | |
| GO:0007275: Multicellular organismal development | 87 | 6.80 × 10-5 | |
| GO:0048468: Cell development | 31 | 8.17 × 10-5 | |
| GO:0032502: Developmental process | 91 | 1.82 × 10-4 | |
| GO:0048869: Cellular developmental process | 59 | 5.41 × 10-4 | |
| GO:0030154: Cell differentiation | 57 | 5.74 × 10-4 | |
| GO:0048513: Organ development | 56 | 0.0036 | |
| GO:0045595: Regulation of cell differentiation | 18 | 0.0083 | |
| 35 | 2.34 × 10-10 to 0.022 | ||
| GO:0005576: Extracellular region | 81 | 2.34 × 10-10 | |
| GO:0044421: Extracellular region part | 43 | 2.70 × 10-7 | |
| GO:0031012: Extracellular matrix | 22 | 1.16 × 10-5 | |
| GO:0005578: Proteinaceous extracellular matrix | 21 | 2.14 × 10-5 | |
| GO:0005615: Extracellular space | 24 | 0.0020 | |
| GO:0044420: Extracellular matrix part | 7 | 0.0202 | |
| 227 | 2.46 × 10-16 to 1.01 × 10-6 | ||
| GO:0005886: Plasma membrane | 134 | 2.46 × 10-16 | |
| GO:0031224: Intrinsic to membrane | 191 | 1.07 × 10-8 | |
| GO:0044425: Membrane part | 215 | 2.08 × 10-8 | |
| GO:0016020: Membrane | 226 | 7.80 × 10-8 | |
| GO:0031224: Intrinsic to membrane | 178 | 1.01 × 10-6 | |
1P-value of enrichment of GO terms using DAVID analysis software; similar results were found with GOstat.
Figure 4Visual representation of DE genes associated with cytoskeletal components.
Figure 5Visual representation of Wnt signalling pathway components, showing altered expression in developing muscle-less humeri. Blue circles indicate down-regulated genes red are up-regulated genes (Fold change ≥2, p ≤ 0.05, genes and details listed in Table 7).
Differentially expressed Wnt signalling pathway genes
| # | 41.05 | Fgf4 | Fibroblast growth factor 4 | | | | T | [ |
| # | | Snai3 | Snail homolog 3 | | | | PT | Snai1
[ |
| 90.87 | 32.06 | Cacng1 | Calcium channel, voltage-dependent, gamma subunit 1 | | | | T | [ |
| 42.86 | 18.77 | Pitx3 | Paired-like homeodomain transcription factor 3 | | | | PT | Pitx2
[ |
| 37.43 | 17.22 | Kremen2 | Kringle containing transmembrane protein 2 | | Co-Rec | | [ | |
| 29.52 | | Ccnb3 | Cyclin B3 | | | | PT | CyclinD1
[ |
| 12.29 | 7.05 | Rxrg | Retinoid X receptor gamma | | | | PT | Rarg
[ |
| 5.95 | 5.20 | Islr2 | Immunoglobulin superfamily containing leucine-rich repeat 2 | | | PT | Islr
[ | |
| 4.87 | | Pitx2 | Paired-like homeodomain transcription factor 2 | | | | T | [ |
| 3.58 | | Fzd10 | Frizzled homolog 10 | | R | | | [ |
| 3.16 | 2.21 | Dll1 | Delta-like 1 | | | | T | [ |
| 3.05 | | Prg4 | Lubricin | | | | T | [ |
| 2.81 | 2.57 | Lrrn1 | Leucine rich repeat protein 1, neuronal | | | | T | [ |
| 2.52 | | Sall1 | Sal-like 1 | | | | PT | Sall4:
[ |
| 2.47 | | Tnik | TRAF2 and NCK interacting kinase | | | TF-act | [ | |
| 2.32 | | Tcf15 | Transcription factor 15 | | | | T | |
| 2.32 | | Met | Met proto-oncogene | | | | T | [ |
| 2.18 | 2.28 | Cd44 | CD44 antigen | | | | T | [ |
| 2.09 | | Jag2 | Jagged2 | | | | PT | Jag1
[ |
| Up-regulated Wnt pathway genes | ||||||||
| 4.36 | 4.91 | Grem2 | Gremlin | | | | T | [ |
| 3.96 | | Wnt2 | Wingless-related MMTV integration site 2 | L | | | | |
| 3.50 | | Wnt2b | Wingless-related MMTV integration site 2b | L | | | | |
| 3.07 | | Wnt16 | Wingless-related MMTV integration site 16 | L | | | | |
| 2.85 | 2.90 | Kcnd2 | Potassium voltage-gated channel, shal-related family, member 2 | | T | [ | ||
| 2.73 | | Cldn1 | Claudin-1 | | | | T | [ |
| 2.44 | | Dkk2 | Dickkopf | Ant | | T | [ | |
| 2.43 | 3.08 | Rspo2 | R-spondin 2 | L | | | T | [ |
| 2.37 | | Epha4 | Eph receptor A4 | | | | T | [ |
| 2.11 | | Elavl2 | ELAV (embryonic lethal, abnormal vision, Drosophila)-like 2 | | T | [ | ||
| 2.10 | | Cpz | Carboxypeptidase Z | Co-act | | | [ | |
| 2.09 | 2.62 | Sfrp2 | Secreted frizzled related protein 2 | Ant | | T | [ | |
| 2.03 | | Wnt4 | Wingless-related MMTV integration site 4 | L | | | | |
| 2.02 | | Rspo3 | R-spondin 3 | L | | | T | [ |
| 2.41 | E330013P04Rik | RIKEN cDNA E330013P04 gene | T | [ | ||||
#No numerical value for fold change as no transcripts detected in the Mutant.
T -Target, PT -Potential Target, R -Receptor, Co-Rec -Co-Receptor, TF-act -Transcription Factor activator, L -Ligand, Ant -Antagonist, Co-act -Co-activator.
Differentially expressed genes associated with other signalling pathways
| | | ||||
|---|---|---|---|---|---|
| | |||||
| 87.94 | 50.88 | Hfe2 | Hemochromatosis type 2 | Co-Rec | [ |
| 5.25 | | Fgf8 | Fibroblast growth factor 8 | T | [ |
| 2.44 | | Scx | Scleraxis | T | [ |
| 2.17 | | Egr2 | Early growth response 2 | T | [ |
| 2.03 | | Bmp3 | Bone morphogenetic protein 3 | L | |
| Hedgehog signalling pathway | |||||
| 14.55 | 4.59 | Hhatl | Hedgehog acyltransferase-like | L-act | [ |
| 2.70 | | Ptchd1 | Patched domain containing 1 | R | |
| 2.27 | | Hhip | Hedgehog interacting protein | Ant, T | [ |
| 2.14 | | Ptch1 | Patched 1 | T | [ |
| Fibroblast growth factor signalling pathway | |||||
| # | | Fgf4 | Fibroblast growth factor 4 | L | |
| # | | Fgf6 | Fibroblast growth factor 5 | L | |
| 5.25 | | Fgf8 | Fibroblast growth factor 8 | L | |
| 5.10 | | Fgf5 | Fibroblast growth factor 5 | L | |
| 4.54 | 3.23 | Fgfr4 | Fibroblast growth factor receptor 4 | R | |
| 3.24 | | Spry1 | Sprouty homolog 1 | Ant | [ |
| 3.22 | | Spry4 | Sprouty homolog 4 | Ant | |
| 2.75 | | Spry2 | Sprouty homolog 2 | Ant | [ |
| 2.39 | | Fgf2 | Fibroblast growth factor 2 | L | |
| 2.134 | 2.48 | Fgf10 | Fibroblast growth factor 10 | L | |
| Hippo signalling pathway | |||||
| 98.29 | 49.05 | Vgll2 | Vestigial like 2 homolog (Drosophila) | Co-TF | [ |
| 3.86 | 4.38 | Tead4 | TEA domain family member 4 | Co-TF | [ |
| 2.96 | | Fat4 | Fat tumor suppressor homolog 4 | R | [ |
| 2.43 | | Fat2 | Fat tumor suppressor homolog 2 | R | [ |
| Notch signalling pathway | |||||
| 5.64 | | Dner | Delta/notch-like EGF-related receptor | R | [ |
| 3.16 | 2.21 | Dll1 | Delta-like 1 (Drosophila) | L | [ |
| 2.69 | | Hes6 | Hairy and enhancer of split 6 | T | [ |
| 2.54 | | Dtx4 | Deltex homolog 4 | T | [ |
| 2.09 | | Jag2 | Jagged 2 | R | [ |
| 3.25 | 2.87 | Nrg1 | Neuregulin 1 | T | [ |
| 2.36 | 2.09 | Foxc2 | Forkhead box C2 | Upstream-activator | [ |
| 2.27 | 2.29 | Cntn1 | Contactin 1 | PL | [ |
#No numerical value for fold change as no transcripts detected in the Mutant.
Co-Rec -Co-Receptor, T -Target, L -Ligand, L-act- Ligand activator, R -Receptor, Ant -Antagonist, Co-TF- -Co-Transcription Factor, PL –Potential Ligand.
Primer sequences for qRT-PCR analysis of differentially expressed genes
| Fgf4 | Fwd | CCGACGAGTGTAAATTCAAAGAAA | 97 |
| Rv | TTCTTACTGAGGGCCATGAACA | ||
| Cilp | Fwd | AAAAAGACGGCTTTCCAAATCA | 78 |
| Rv | GGCATAGATAGGCCCATTGC | ||
| Rxrg | Fwd | CGTTGAGTGGGCCAAACG | 75 |
| Rv | CCTGCCCGGAGTAGAATGAC | ||
| Dll1 | Fwd | GACCGCCGCTTCCTAATAGG | 74 |
| Rv | GCCCAGATGTTCAGCTTAATTCC | ||
| Spp1 | Fwd | CCCTCGATGTCATCCCTGTT | 69 |
| Rv | TGCCCTTTCCGTTGTTGTC | ||
| Vstm2a | Fwd | GTGGAGCTCTTACCCGACAGA | 73 |
| Rv | CATTGCCTTGGACTTTCACTGTAC | ||
| Figf | Fwd | GGTTGCCTGAAACAGAGTAGTAGGT | 71 |
| Rv | AGCATTGCCCTTGGACTTTG | ||
| Fgf10 | Fwd | GGGCTGCTGTTGCTGCTT | 94 |
| Rv | GGCCTCCTGTGACACCATGT | ||
| Sfrp2 | Fwd | CAGAGAGAGTTCAAGCGCATCTC | 68 |
Figure 6Comparison of spatial distribution of differentially expressed genes in TS23 control (A,C,E,G,I,K,M) and TS23 mutant (B,D,F,H,J,L,N,P) elbow joint, shoulder joint, humerus, radius and ulna.Cd44(A-D) expression in the elbow joint (A-B), and the shoulder joint (C-D) (arrows in B and D indicate the position of joint-line cells based on cell morphology), Sfrp2(E-H) expression in the elbow joint (E-F) (arrow indicates abnormal expression on the ventral side of the joint), and the shoulder joint (G-H), Wnt4 expression in the elbow joint (I-J), and the shoulder joint (K-L), Spp1(K-N) expression in the humerus hypertrophic zone (hz) and perichondrium (p) (M-N) (the arrowhead in L indicates enlarged hypertropic chondrocytes), and in the ulna (u) and radius (r) (O-P). e epidermis. All scale bars are 100 μm.
Details of cDNA clones used as expression probes
| Sfrp2 | Nucleotide 82 to 852 on gene bank sequence U88567 | A. Rattner |
| Cd44 | Nucleotide 222 to 3020 on gene bank sequence NM_00103915.1 | IMAGE Library |
| Spp1 | Nucleotide 27 to 1472 on gene bank sequence NM_001204201 | IMAGE Library |
| Wnt4 | Nucleotide 639 to 1101 on NM_009523.1 | A. McMahon |